Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of patients with atopic dermatitis undergoing systemic therapy during COVID‐19 pandemic in Italy: Data from the DA‐COVID‐19 registry
Andrea Chiricozzi, Mark S. Talamonti, Clara De Simone, et al.
Allergy (2021) Vol. 76, Iss. 6, pp. 1813-1824
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Moderate‐to‐severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real‐world experience
Luca Stingeni, Leonardo Bianchi, Elettra Antonelli, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 8, pp. 1292-1299
Open Access | Times Cited: 38
Teledermatology in the time of COVID‐19
Ahmed Ibrahim, Mayar Magdy, Eslam M. Khalaf, et al.
International Journal of Clinical Practice (2021) Vol. 75, Iss. 12
Open Access | Times Cited: 55
Dupilumab for the treatment of adult atopic dermatitis in special populations
Cataldo Patruno, Luca Potestio, Massimiliano Scalvenzi, et al.
Journal of Dermatological Treatment (2022) Vol. 33, Iss. 7, pp. 3028-3033
Closed Access | Times Cited: 33
Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32‐week real‐world experience during the COVID‐19 pandemic
Katharina Hansel, Cataldo Patruno, Elettra Antonelli, et al.
Clinical and Experimental Dermatology (2021) Vol. 47, Iss. 1, pp. 165-167
Open Access | Times Cited: 26
Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16‐week real‐life experience during the COVID ‐19 pandemic in Italy
Luca Stingeni, Katharina Hansel, Elettra Antonelli, et al.
Dermatologic Therapy (2021) Vol. 34, Iss. 5
Open Access | Times Cited: 25
Allergic diseases and immunodeficiencies in children, lessons learnt from COVID‐19 pandemic by 2022: A statement from the EAACI‐section on pediatrics
Daniel Munblit, Matthew Greenhawt, Helen A. Brough, et al.
Pediatric Allergy and Immunology (2022) Vol. 33, Iss. 10
Open Access | Times Cited: 16
Review of Teledermatology: Lessons Learned from the COVID-19 Pandemic
Jonathan K. Hwang, Natalia Pelet del Toro, George Han, et al.
American Journal of Clinical Dermatology (2023) Vol. 25, Iss. 1, pp. 5-14
Closed Access | Times Cited: 9
Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome
Dimitri Poddighe, Elena Kovzel
Journal of Inflammation Research (2021) Vol. Volume 14, pp. 6845-6853
Open Access | Times Cited: 23
Dupilumab for Atopic Dermatitis—From Clinical Trials to Molecular and Cellular Mechanisms
Beatriz Cabanillas
Dermatitis (2023) Vol. 34, Iss. 1, pp. 21-28
Closed Access | Times Cited: 7
The impact of COVID-19 pandemic on psoriasis patients, and their immunosuppressive treatment: a cross-sectional multicenter study from Turkey
Selda Pelin Kartal, Gökçen Çelik, Oğuz Yılmaz, et al.
Journal of Dermatological Treatment (2021) Vol. 33, Iss. 4, pp. 2137-2144
Closed Access | Times Cited: 16
COVID-19 Clinical Features and Outcome in Italian Patients Treated with Biological Drugs Targeting Type 2 Inflammation
Giada Sambugaro, Elena Brambilla, Giulia Costanzo, et al.
Life (2024) Vol. 14, Iss. 3, pp. 378-378
Open Access | Times Cited: 2
The most common skin symptoms in young adults and adults related to SARS-CoV-2 virus infection
Monika Zaborska, Maksymilan Chruszcz, Jakub Sadowski, et al.
Archives of Dermatological Research (2024) Vol. 316, Iss. 6
Open Access | Times Cited: 2
Drug Survival, Retention, and Persistence of Dupilumab in Adults and Adolescents with Atopic Dermatitis: A Narrative Literature Review
Mariateresa Rossi, Silvia Ferrucci, Piergiacomo Calzavara‐Pinton, et al.
Advances in Therapy (2024)
Open Access | Times Cited: 2
IL-4 receptor blockade is a global repressor of naïve B cell development and responses in a dupilumab-treated patient
John D. Mountz, Min Gao, David M Ponder, et al.
Clinical Immunology (2022) Vol. 244, pp. 109130-109130
Open Access | Times Cited: 11
The effects of systemic immunomodulatory treatments on COVID‐19 outcomes in patients with atopic dermatitis: Results from the global SECURE‐AD registry
Annelie H. Musters, Conor Broderick, David Prieto‐Merino, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 37, Iss. 2, pp. 365-381
Open Access | Times Cited: 10
COVID-19 and Its Impact on Common Diseases in the Allergy Clinics
Emek Kocatürk, Elissa M. Abrams, Marcus Maurer, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 11, pp. 3289-3303
Closed Access | Times Cited: 5
Telemedicine in dermatology
Mónica Paola Novoa-Candia, Valeria Vela-Lopez, Mariana Orduz-Robledo
Biomedical engineering (2024)
Open Access | Times Cited: 1
Navigating patients with atopic dermatitis or chronic spontaneous urticaria during the COVID-19 pandemic
Isabelle Haddad, Kathia Kozman, Abdul‐Ghani Kibbi
Frontiers in Allergy (2022) Vol. 3
Open Access | Times Cited: 7
Management of Atopic Dermatitis During the COVID-19 Pandemic: Key Questions and Review of the Current Evidence
Po‐Chien Wu, Chia‐Lun Li, Yun‐Ting Chang, et al.
Dermatitis (2023) Vol. 34, Iss. 2, pp. 77-84
Closed Access | Times Cited: 3
The effect of dupilumab on clinical outcomes in patients with COVID-19: A meta-analysis
Guangyu Ao, Toni Li, Basma Nasr, et al.
Journal of Infection (2023) Vol. 87, Iss. 6, pp. e107-e109
Closed Access | Times Cited: 3
Recent advances and developments in COVID‐19 in the context of allergic diseases
Mei Ding, Xiang Dong, Yuanli Sun, et al.
Clinical and Translational Allergy (2021) Vol. 11, Iss. 7
Open Access | Times Cited: 7
Mental Health Consequences of the COVID-19 Pandemic Long-Term Exposure in Italian Dermatologists
Cristina Ciuluvică, Giulio Gualdi, Marco Dal Canton, et al.
International Journal of Environmental Research and Public Health (2021) Vol. 18, Iss. 21, pp. 11239-11239
Open Access | Times Cited: 5
Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study
Brian D. Rankin, Jorge-Ryan Georgakopoulos, Muskaan Sachdeva, et al.
Journal of Dermatological Treatment (2022) Vol. 33, Iss. 5, pp. 2692-2694
Closed Access | Times Cited: 3
COVID-19 in Patients with Atopic Dermatitis Treated with Dupilumab: Three Cases and a Literature Review
Justyna Ceryn, Michał Niedźwiedź, Małgorzata Skibińska, et al.
Clinical Cosmetic and Investigational Dermatology (2021) Vol. Volume 14, pp. 1131-1138
Open Access | Times Cited: 4
Clinical improvement of atopic dermatitis in two patients co‐affected with non‐severe COVID‐19 infection: A case series and review of literature
Gaetano Licata, Dario Buononato, Carmine Fiorentino, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 5
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top